P18.04: Migration of initially properly placed Mirena levonorgestrel-releasing intrauterine device (IUD) in two patients: case report

Hypertension and use of an intrauterine levonorgestrel-releasing device.

Levonorgestrel-releasing (20mcg/day) intrauterine systems (Mirena) compared with other methods of reversible contraceptives.

OBJECTIVE To assess the relative contraceptive effectiveness, tolerability and acceptability of the levonorgestrel-releasing (20 microg per day) intrauterine system (LNG-20) compared with reversible contraceptive methods in women of reproductive age. DESIGN A systematic review and meta-analysis of randomised controlled trials. IDENTIFICATION Studies were identified through seven databases, ...

Levonorgestrel-Releasing Intrauterine Device-Related Acute Liver Injury

Oral contraceptives have long been associated with liver injury. However, very little attention is paid to the metabolic side effects of hormone-releasing intrauterine devices (IUDs). These devices are generally considered safe and commonly used. We report for the first time acute liver injury associated with a levonorgestrel-releasing IUD. Our patient did not have any comorbidities that could ...

Levonorgestrel-releasing intrauterine system (Mirena) in compare to medroxyprogesterone acetate as a therapy for endometrial hyperplasia

BACKGROUND This study was designed to evaluate the comparison of insertion of levonorgestrel (LNG)-releasing intrauterine system versus oral medroxyprogesterone acetate on endometrial hyperplasia in a randomized controlled trial. MATERIALS AND METHODS A total of 60 women with the initial histopathological diagnosis of endometrial hyperplasia in two groups received LNG or medroxyprogesterone (...

Endometrial adenocarcinoma in association with a levonorgestrel-releasing intrauterine system (Mirena).

The levonorgestrel-releasing intrauterine system (LNGIUS), Mirena®, has been licensed as a contraceptive in the UK since 1995. In 2002, Mirena became licensed also for the management of idiopathic menorrhagia and in 2004 the product licence was extended further to use for “endometrial protection” to prevent endometrial hyperplasia in women receiving oestrogen replacement therapy. We report a ca...